IMVT · Healthcare
Immunovant Inc
15/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
20
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$8.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About IMMUNOVANT INC
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Who's behind the signal
Every informed buyer we can see on IMVT, across all three feeds.
Hedge funds · 4
D.E. Shaw & Co
New position
Gotham Asset Mgmt (Greenblatt)
New position
AQR Capital Management
New position
Citadel Advisors
Increased +11%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
IMMUNOVANT INC isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
3
New positions
1
Increasing
0
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
NEW
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+11%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to IMMUNOVANT INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell IMMUNOVANT INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime